ClinicalTrials.gg
CompletedNCT00115492Updated Jan 20, 2017

Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations

A Phase 4 interventional study of Fluticasone Propionate/Salmeterol Combination Product and Salmeterol in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 110 sites in 2 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2017-01-20.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
797
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 43 studies testing Salmeterol Xinafoate in Pulmonary Disease, Chronic Obstructive — none open to participants now, none under way, none of them phase 3. Salmeterol Xinafoate · Pulmonary Disease, Chronic Obstructive.

Enrollment
6th of 43
797 · median 107
Started
2004
with 2 others
Phase 4
22 of 43
none open now
Registered
1st of 43
by date
Lead sponsor
16 of 43
GlaxoSmithKline

Among the 43 studies testing Salmeterol Xinafoate in Pulmonary Disease, Chronic Obstructive, this one is the 6th largest by enrollment, is one of 3 that started in 2004, is one of 22 in phase 4, and was the 1st registered.

Pulmonary Disease, Chronic Obstructive

5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

None of the 43 studies testing Salmeterol Xinafoate in Pulmonary Disease, Chronic Obstructive is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →

About Salmeterol Xinafoate

Salmeterol Xinafoate: first FDA approval 1994 (SEREVENT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 43 studies testing Salmeterol Xinafoate in Pulmonary Disease, Chronic Obstructive as a file.
02

Study summary

This study evaluates the effect of two medicines on COPD (Chronic Obstructive Pulmonary Disease) exacerbations. This study will last up to 56 weeks, and subjects will visit the clinic 10 times. Subjects will be given breathing tests and will record their breathing symptoms daily on diary cards. All study related medicines and medical examinations will be provided at no cost. The two drugs used in this study have been approved by FDA for use in patients with COPD.

Read the detailed description

A Randomized, Double-Blind, Parallel Group, 52-week Study to Compare the Effect of the Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50mcg BID with Salmeterol DISKUS 50mcg BID on the Annual Rate of Moderate/Severe Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD)

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive

Keywords

  • Breathing
  • Exacerbation
  • Chronic Obstructive Pulmonary Disease
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of .
  • Current or previous cigarette smokers with a smoking history of at least 10 pack-years.
  • History of at least 1 COPD exacerbation in the 12 months prior to screening.
  • (FEV1) of less than or equal to 50% of predicted normal.

Exclusion criteria

Exclusion criteria:

  • Diagnosis of asthma.
  • Additional respiratory disorders other than (eg, sarcoidosis, alpha-1 antitrypsin deficiency, cystic fibrosis, or active tuberculosis).
  • Concurrent use of long-acting beta-agonists, long-acting anticholinergics, inhaled and oral , theophylline, medications, ritonavir, and anti-leukotrienes.
  • Lung resection surgery within 1 year of screening.
  • Abnormal and findings at screening.
  • Other inclusion and exclusion criteria will be evaluated at the first study visit.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
797 participants (actual)

Interventions

  • DrugFluticasone Propionate/Salmeterol Combination Product
  • Also known as: Fluticasone Propionate/Salmeterol Combination Product

06

What researchers measure

Primary outcomes

  1. Rate of moderate/severe exacerbations over a 52 week treatment period

Secondary outcomes

  1. The time until the first moderate/severe exacerbation; the annual rate of exacerbations requiring oral corticosteroid treatment, and breathing tests conducted over one year

07

Study locations

110 sites
  • GSK Investigational Site
    Jasper, Alabama 35501, United States
  • GSK Investigational Site
    Mobile, Alabama 36608, United States
  • GSK Investigational Site
    Glendale, Arizona 85306, United States
  • GSK Investigational Site
    Phoenix, Arizona 85013, United States
  • GSK Investigational Site
    Berkeley, California 94705, United States
  • GSK Investigational Site
    Fullerton, California 92835, United States
  • GSK Investigational Site
    Riverside, California 92506, United States
  • GSK Investigational Site
    Sacramento, California 95825, United States
  • GSK Investigational Site
    San Diego, California 92123, United States
  • GSK Investigational Site
    Vista, California 92084, United States
  • GSK Investigational Site
    Fort Collins, Colorado 80528, United States
  • GSK Investigational Site
    Stamford, Connecticut 06902, United States
  • GSK Investigational Site
    Atlantis, Florida 33462, United States
  • GSK Investigational Site
    Clear Water, Florida 33756, United States
  • GSK Investigational Site
    Deland, Florida 32720, United States
  • GSK Investigational Site
    Fort Lauderdale, Florida 33316, United States
  • GSK Investigational Site
    Pensacola, Florida 32504, United States
  • GSK Investigational Site
    Sarasota, Florida 34239, United States
  • GSK Investigational Site
    Tamarac, Florida 33321, United States
  • GSK Investigational Site
    Atlanta, Georgia 30342, United States
  • GSK Investigational Site
    Woodstock, Georgia 30189, United States
  • GSK Investigational Site
    Springfield, Illinois 62702, United States
  • GSK Investigational Site
    Elkhart, Indiana 46154, United States
  • GSK Investigational Site
    Evansville, Indiana 47710, United States
  • GSK Investigational Site
    Evansville, Indiana 47714, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46208, United States
  • GSK Investigational Site
    South Bend, Indiana 46617, United States
  • GSK Investigational Site
    Iowa City, Iowa 52242, United States
  • GSK Investigational Site
    Olathe, Kansas 66061, United States
  • GSK Investigational Site
    Madisonville, Kentucky 42431, United States
  • GSK Investigational Site
    Lafayette, Louisiana 70503, United States
  • GSK Investigational Site
    New Orleans, Louisiana 70112, United States
  • GSK Investigational Site
    Shreveport, Louisiana 71103, United States
  • GSK Investigational Site
    Sunset, Louisiana 70584, United States
  • GSK Investigational Site
    Auburn, Maine 04210, United States
  • GSK Investigational Site
    Baltimore, Maryland 21201, United States
  • GSK Investigational Site
    Boston, Massachusetts 02135, United States
  • GSK Investigational Site
    St. Joseph, Michigan 49085, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55407, United States
  • GSK Investigational Site
    Chesterfield, Missouri 63017, United States
  • GSK Investigational Site
    Jefferson City, Missouri 65101, United States
  • GSK Investigational Site
    St. Charles, Missouri 63301, United States
  • GSK Investigational Site
    St. Louis, Missouri 63110, United States
  • GSK Investigational Site
    Billings, Montana 59102, United States
  • GSK Investigational Site
    Butte, Montana 59701, United States
  • GSK Investigational Site
    Omaha, Nebraska 68124, United States
  • GSK Investigational Site
    Omaha, Nebraska 68131, United States
  • GSK Investigational Site
    Absecon, New Jersey 08201, United States
  • GSK Investigational Site
    Albany, New York 12205, United States
  • GSK Investigational Site
    Bayshore, New York 11706, United States
  • GSK Investigational Site
    Ithaca, New York 14850, United States
  • GSK Investigational Site
    Larchmont, New York 10538, United States
  • GSK Investigational Site
    New York, New York 10016, United States
  • GSK Investigational Site
    Chapel Hill, North Carolina 27599, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28207, United States
  • GSK Investigational Site
    Elizabeth City, North Carolina 27909, United States
  • GSK Investigational Site
    High Point, North Carolina 27262, United States
  • GSK Investigational Site
    Raleigh, North Carolina 27612, United States
  • GSK Investigational Site
    Winston-Salem, North Carolina 27157, United States
  • GSK Investigational Site
    Canton, Ohio 44718, United States
  • GSK Investigational Site
    Chardon, Ohio 44024, United States
  • GSK Investigational Site
    Mogadore, Ohio 44260, United States
  • GSK Investigational Site
    Lake Oswego, Oregon 97035, United States
  • GSK Investigational Site
    Erie, Pennsylvania 16508, United States
  • GSK Investigational Site
    Hershey, Pennsylvania 17033, United States
  • GSK Investigational Site
    McKeesport, Pennsylvania 15132, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15025, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15243, United States
  • GSK Investigational Site
    East Providence, Rhode Island 02914, United States
  • GSK Investigational Site
    Providence, Rhode Island 2909, United States
  • GSK Investigational Site
    Gaffney, South Carolina 29340, United States
  • GSK Investigational Site
    Greer, South Carolina 29651, United States
  • GSK Investigational Site
    Simpsonville, South Carolina 29681, United States
  • GSK Investigational Site
    Spartanburg, South Carolina 29303, United States
  • GSK Investigational Site
    Bristol, Tennessee 37620, United States
  • GSK Investigational Site
    Chattanooga, Tennessee 37403, United States
  • GSK Investigational Site
    Johnson City, Tennessee 37601, United States
  • GSK Investigational Site
    Kingsport, Tennessee 37660, United States
  • GSK Investigational Site
    Dallas, Texas 75390-9016, United States
  • GSK Investigational Site
    Houston, Texas 77074, United States
  • GSK Investigational Site
    New Braunfels, Texas 78130, United States
  • GSK Investigational Site
    San Antonio, Texas 78217, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    San Marcos, Texas 78666, United States
  • GSK Investigational Site
    Abingdon, Virginia 24210, United States
  • GSK Investigational Site
    Lynchburg, Virginia 24501, United States
  • GSK Investigational Site
    Newport News, Virginia 23606, United States
  • GSK Investigational Site
    Richmond, Virginia 23225, United States
  • GSK Investigational Site
    Bellingham, Washington 98226, United States
  • GSK Investigational Site
    Gig Harbor, Washington 98335, United States
  • GSK Investigational Site
    Kirkland, Washington 98034, United States
  • GSK Investigational Site
    Spokane, Washington 99204, United States
  • GSK Investigational Site
    Morgantown, West Virginia 26505, United States
  • GSK Investigational Site
    La Crosse, Wisconsin 54601, United States
  • GSK Investigational Site
    Milwaukee, Wisconsin 53209, United States
  • GSK Investigational Site
    Vancouver, British Columbia V5Z 3J5, Canada
  • GSK Investigational Site
    Winnipeg, Manitoba R2K 3S8, Canada
  • GSK Investigational Site
    Saint John, New Brunswick E2M 3W5, Canada
  • GSK Investigational Site
    Bay Roberts, Newfoundland and Labrador A0G 1G0, Canada
  • GSK Investigational Site
    Holyrood, Newfoundland and Labrador A0A 2R0, Canada

Showing the first 100 of 110 sites across 2 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Disantostefano RL, Li H, Rubin DB, Stempel DA. Which patients with chronic obstructive pulmonary disease benefit from the addition of an inhaled corticosteroid to their bronchodilator? A cluster analysis. BMJ Open. 2013 Apr 22;3(4):e001838. doi: 10.1136/bmjopen-2012-001838. Print 2013. PubMed 23613569 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2004, a primary completion of Jun 2007 and a completion of Jun 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2005
First posted
Jun 23, 2005
Start
Dec 2004
Primary completionActual
Jun 2007
CompletionActual
Jun 2007
Last update
Jan 20, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00115492
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jun 23, 2005
Start date
Dec 2004
Primary completion
Jun 2007
Completion
Jun 2007
Last update
Jan 20, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Salmeterol Xinafoate

Start the discussion